

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 October 2005 (13.10.2005)

PCT

(10) International Publication Number
WO 2005/095450 A2

(51) International Patent Classification⁷: **C07K 14/475**

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(21) International Application Number:
PCT/EP2005/051431

(22) International Filing Date: 30 March 2005 (30.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2004 00510 30 March 2004 (30.03.2004) DK
60/575,086 28 May 2004 (28.05.2004) US
PA 2004 00843 28 May 2004 (28.05.2004) DK

(71) Applicant (for all designated States except US): NSGENE
A/S [DK/DK]; Baltorpevej 154, DK-2750 Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRØNBORG,
Mette [DK/DK]; Nebbegårdsbakken 51, DK-2400 Køben-
havn NV (DK). KUSK, Philip [DK/DK]; Baunesvinget
20, DK-3540 Lyngby (DK). BLOM, Nikolaj [DK/DK];
Nebbegårdsbakken 51, DK-2400 København NV (DK).
PETERSEN, Thomas, Nordahl [DK/DK]; Hillerødsgade
55, st. th., DK-2200 København N (DK). JOHANSEN,
Telt, E. [DK/DK]; Stampeengen 26, DK-2970 Hørsholm
(DK). BRUNAK, Søren [DK/DK]; Gammel Vartov
Vej 22, DK-2900 Hellerup (DK). WAHLBERG, Lars
[SE/DK]; Veddingevej 14 Høve, DK-4550 Asnæs (DK).

(74) Agent: NØRGAARD, Jens Viktor; NsGene A/S, Baltor-
pevej 154, DK-2750 Ballerup (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished
upon receipt of that report
- with sequence listing part of description published sepa-
rately in electronic form and available upon request from
the International Bureau

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC USE OF A GROWTH FACTOR, NSG33

(57) **Abstract:** The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the inven-
tion relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of
disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal
potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The
invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.

WO 2005/095450 A2